Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 7 (2010), Issue 2 (February)

1. Concomitant and successive amplifications of MYC in APL-like leukemia.
   Cancer Genet Cytogenet, 197(1): 75-80. [Abstract] [Full-text]
2. Coexistence of alternative MLL-SEPT9 fusion transcripts in an acute myeloid leukemia with t(11;17)(q23;q25).
   Cancer Genet Cytogenet, 197(1): 60-4. [Abstract] [Full-text]
3. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
   Leuk Res, 34(2): 196-202. [Abstract] [Full-text]
4. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes.
   Leuk Res, 34(2): 148-53. [Abstract] [Full-text]
5. BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients.
   Leuk Res, 34(2): 166-72. [Abstract] [Full-text]
6. t(X;17) as the sole karyotypic anomaly in a case of M(3r) subtype of acute promyelocytic leukemia without RARalpha rearrangement.
   Leuk Res, 34(2): e55-7. [Abstract] [Full-text]
7. Molecular identification of the HLA-DRB1-DQB1 for diagnosis and follow-up of acute leukemias.
   Blood Cells Mol Dis, 44(2): 69-73. [Abstract] [Full-text]
8. Randomized clinical trials with biomarkers: design issues.
   J Natl Cancer Inst, 102(3): 152-60. [Abstract] [Full-text]
9. Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse.
   Eur J Haematol, 84(2): 128-32. [Abstract] [Full-text]
10. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
    Blood, 115(5): 948-56. [Abstract] [Full-text]
11. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
    J Clin Oncol, 28(5): 808-14. [Abstract] [Full-text]
12. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
    J Clin Oncol, 28(5): 815-21. [Abstract] [Full-text]
13. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis.
    Leukemia, 24(2): 438-49. [Abstract] [Full-text]
14. Pirin downregulation is a feature of AML and leads to impairment of terminal myeloid differentiation.
    Leukemia, 24(2): 429-37. [Abstract] [Full-text]
15. Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features.
    Am J Clin Pathol, 133(3): 484-90. [Abstract] [Full-text]
16. C-C chemokine receptor 1 expression in human hematolymphoid neoplasia.
    Am J Clin Pathol, 133(3): 473-83. [Abstract] [Full-text]
17. NDRG1/2 expression is inhibited in primary acute myeloid leukemia.
    Leuk Res, 34(3): 393-8. [Abstract] [Full-text]
18. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
    Leuk Res, 34(3): 403-5. [Abstract] [Full-text]
19. Fluorescence in situ hybridization for del(5q) in myelodysplasia/acute myeloid leukemia: comparison of EGR1 vs. CSF1R probes and diagnostic yield over metaphase cytogenetics alone.
    Leuk Res, 34(3): 340-3. [Abstract] [Full-text]
20. NB4 cells treated with all-trans retinoic acid generate toxic reactive oxygen species that cause endothelial hyperpermeability.
    Leuk Res, 34(3): 373-8. [Abstract] [Full-text]
21. Central nervous system involvement at the time of presentation in acute promyelocytic leukemia.
    Pediatr Blood Cancer, 54(4): 603-5. [Abstract] [Full-text]
22. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
    J Clin Oncol, 28(6): 955-9. [Abstract] [Full-text]
23. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.
    J Clin Oncol, 28(6): 1047-53. [Abstract] [Full-text]
24. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.
    Blood, 115(7): 1406-15. [Abstract] [Full-text]
25. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
    Blood, 115(7): 1425-32. [Abstract] [Full-text]
26. Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.
    Blood, 115(7): 1433-43. [Abstract] [Full-text]
27. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Ann Hematol, 89(4): 365-74. [Abstract] [Full-text]
28. Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
    Leuk Res, 34(4): 498-506. [Abstract] [Full-text]
29. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia.
    Leuk Res, 34(4): 545-7. [Abstract] [Full-text]
30. Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.
    Leuk Res, 34(4): 487-91. [Abstract] [Full-text]
31. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.
    Leuk Res, 34(4): 535-41. [Abstract] [Full-text]
32. Expression proteomics of acute promyelocytic leukaemia cells treated with methotrexate.
    Biochim Biophys Acta, 1804(4): 918-28. [Abstract] [Full-text]

© 2004-2012 Acute Myeloid Leukemia Research Today. All Rights Reserved.